Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer

Medical Decision Making

Volumn 18, Issue 3, 1998, Pages 256-267

  Brundage, Michael D ^a   Davidson, Judith R ^b   Mackillop, William J ^b   Feldman Stewart, D E B ^b   Groome, Patti ^b  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

Lung cancer; Patient decision making; Policy; Treatment tradeoffs

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DECISION MAKING; FEMALE; HEALTH CARE POLICY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; SCORING SYSTEM;

AGED; ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CHOICE BEHAVIOR; DECISION SUPPORT TECHNIQUES; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031748935     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X9801800302     Document Type: Article

References (52)

1. Boring CC, Squires TS, Tong MS, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994;44:7-26.
2. Anonymous, Canadian Cancer Statistics. Toronto, ON, Canada: National Cancer Institute of Canada, 1996.
3. Mountain CF. A new international staging system for non-small cell lung cancer. Chest. 1986;89:225s-233s.
4. Brundage MD, Mackillop WJ. Locally advanced non-small cell lung cancer: do we know the questions? J Clin Epidemiol. 1996;49:183-92.
5. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-81.
6. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-5.
7. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83: 417-23.
8. Sause W, Scott C, Taylor S, et al. RTOG 88-08 and ECOG 4588: preliminary analysis of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;8713:198-205.
9. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiation Oncol Biol Phys. 1992;24: 11-5.
10. Pignon JP, Stewart LA, Souhami RL, Arriagada R. A meta-analysis using individual patient data from randomized clinical trials of chemotherapy in non-small cell lung cancer: 2. Survival in the locally advanced setting (abstr). ASCO Proc. 1994;13:334.
11. Green MR. Chemotherapy and radiation in the nonoperative management of stage III non-small-cell lung cancer: the right chemotherapy works in the right setting. In: DeVita VT (ed). Important Advances in Oncology 1993. Philadelphia, PA: J. B. Lippincott, 1993:125-38.
12. Mackillop WJ, O'Sullivan B, Ward GK. Non-small cell lung cancer: how oncologists want to be treated. Int J Radiation Oncol Biol Phys. 1987;13:929-34.
13. Palmer MJ, O'Sullivan B, Steele R, Mackillop WJ. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol. 1990; 19:17-28.
14. Mackillop WJ, Ward GK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer. 1986;54:661-7.
15. Murray N. Chemotherapy for nonsmall cell lung cancer: a futile or fertile field for clinical research? Can J Clin Oncol. 1993;3:151-60.
16. Hamilton CS, Denham JW, Joseph DJ, et al. Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian patterns of practice study. Newcastle Mater Misericordiae Hospital, New South Wales, Australia. Clin Oncol. 1992;4:141-7.
17. Priestman TJ, Bullimore JA, Godden TP. The Royal College of Radiologists' Fractionation Survey. Clin Oncol. 1989;1:39-46.
18. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol. 1995;13:1904-11.
19. Brundage MD, Davidson JR, Groome PA, Fcldman-Stewart D, Mackillop WJ. Decision analysis in locally advanced non-small cell lung cancer - is it useful? J Clin Oncol. 1997;15: 873-83.
20. Llewellyn-Thomas HA, Williams JI, Levy L, Naylor CD. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making. 1996;16:262-72.
21. Llewellyn-Thomas HA, McGreal MJ. Thiel EC, Fine S, Erlichman C. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med. 1991;32:35-42.
22. Llewellyn-Thomas HA, Thiel EC, Clark RM. Patients versus surrogates: whose opinion counts on ethics review panels? Clin Res. 1989;37:501-5.
23. O'Connor AM, Boyd NF, Warde P, Stolbach L, Till JE. Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. J Chronic Dis. 1987;40:811-8.
24. Palda V, Llewellyn-Thomas H, MacKenzie RG, Pritchard KI, Harrison-Woermke DE, Naylor CD. Breast cancer patients' perceptions of the effectiveness of radiation therapy (abstr). Med Decis Making. 1994;14:438.
25. Kiebert GM, Stiggelbout AM, Leer JH, Kievit J, de Haes JCJM. Test-retest reliabilities of two treatment-preference instruments in measuring utilities. Med Decis Making. 1993;13: 133-40.
26. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40:593-600.
27. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced lung cancer. J Clin Oncol. 1997;15:330-40.
28. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. The Statistician. 1983;32: 307-17.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-10.
30. Weinstein MC, Fineberg HV. The value of clinical information. In: Clinical Decision Analysis. Toronto, ON, Canada: W. B. Saunders, 1980:131-67.
31. Bleehen NM. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Br J Cancer. 1992; 65:934-41.
32. Dixon P. Palliative radiotherapy in Canada. Can J Oncol. 1996;6(s):74-83.
33. Schaake-Koning C, Van Den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326: 524-30.
34. Stewart LA, Pignon JP. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909.
35. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford, U.K.: Blackwell Scientific Publications, 1985.
36. Brown MB, Benedetti JK. Sampling behavior of tests for correlation in two-way contingency tables. J Am Stat Assoc. 1977; 72:309-15.
37. Kendall M, Stewart A. The Advanced Theory of Statistics. Vol 2. New York: Macmillan, 1979.
38. Frisch D, Clemen RT. Beyond expected utility: rethinking behavioral decision research. Psychol Bull. 1994;116:46-54.
39. Llewellyn-Thomas HA. Turning decision analysis around. Ann R Coll Phys Surg Can. 1994;27:177-8.
40. Hammond KR. Human judgment and social policy; irreducible uncertainty, inevitable error, unavoidable injustice. New York: Oxford University Press, 1996.
41. Hammond KR. How convergence of research paradigms can improve research on diagnostic judgment. Med Decis Making. 1996;16:281-7.
42. Kahneman D, Slovic P, Tversky A (eds). Judgment under uncertainty: heuristics and biases. Cambridge, U.K.: Cambridge University Press, 1982.
43. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler D, Cummings BJ. Whose utilities for decision analysis? Med Decis Making. 1990;10:58-67.
44. Davidson JR, Brundage MD. What information do people need before choosing a cancer treatment? (abstr). Med Decis Making. 1994;14:426.
45. Feldman-Stewart D, Chammas S, Hayter C, Pater J, Mackillop WJ. An empirical approach to informed consent in ovarian cancer. J Clin Epidemiol. 1996;49:1259-69.
46. Kocovski N. Effects of presentation format on the accuracy and efficiency of the perception of quantitative information. Unpublished honour's dissertation. Queen's University, Kingston, ON, Canada, 1996.
47. Streiner DL, Norman GR. Health Measurement Scales - A Practical Guide to Their Development and Use. 2nd ed. New York: Oxford University Press, 1995.
48. Feinstein AR, Kramer MS. Clinical biostatistics LII. A primer on quantitative indexes of association. Clin Pharmacol Ther. 1980;28:130-45.
49. McNeil BJ, Weichselbaum RR, Pauker SG. Fallacy of the five-year survival in lung cancer. N Engl J Med. 1978;299:1397-401.
50. McNeil BJ, Weichselbaum RR, Pauker SG. Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med. 1981;305:982-7.
51. Sutherland HJ, Lockwood GA, Tritchler DL, Sem F, Brooks L, Till JE. Communicating probabilistic information to cancer patients: is there 'noise' on the line? Soc Sci Med. 1991; 32:725-31.
52. Eddy DM. A Manual for Assessing Health Practices and Designing Practice Policies. Philadelphia, PA: American College of Physicians, 1992.